Engineered immune cells take aim at childhood blood cancers
NCT ID NCT06326463
First seen Jan 21, 2026 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This early-phase study tests a new treatment called CD70-CAR T-cells for children and young adults (up to age 21) with blood cancers like leukemia, lymphoma, or MDS that have returned or not responded to standard therapy. The treatment involves taking the patient's own immune cells, modifying them in a lab to recognize and attack cancer cells that carry a protein called CD70, and giving them back through an IV. The main goals are to find the safest dose and see if the cells can reduce or eliminate the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.